Common use of Publications and Presentations Clause in Contracts

Publications and Presentations. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining to the Research Program or any Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed Product, without the prior review by and approval of an authorized representative of the other Party. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Accordingly, each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the public) that relate to the Research Program or any Co-Development Program at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party is given up to [***] days from the date of such written request to seek appropriate patent protection for any material in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or public presentation be deleted prior to such publication or presentation. In any permitted publication or public presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary scientific standards.

Publications and Presentations. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining to the Research Program Annual Budget or any the Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed ProductPlan, without the prior review by and approval of an authorized representative of the other Party. Further, ARCHEMIX WARATAH shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed the Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or ProductsProduct, in accordance with the remainder of this Section 6.35.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder, including adverse effects on patentability. Accordingly, each Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the public) (collectively “Publications”) that relate to the Research Program Product or any Co-to the Development Program at least [***] thirty (30) days prior to its intended public presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] thirty (30) day period, not to submit or present such abstract or manuscript for publication or to make such public presentation Publication until the other Party is given up to [***] sixty (60) days from the date of such written request to seek appropriate patent protection for any material in such intended publication or public presentation that it reasonably believes may be patentable. If ELAN makes a reasonable showing why such Publication may adversely affect patent prosecution or patent procurement strategies which can not be cured by filing a patent application to cover the disclosure, WARATAH agrees to remove the interfering portion from its Publication, or if redaction is not possible, not to publish or present the Publication. Further, WARATAH agrees to provide AZD- 103 and Derivatives and WARATAH Technology to academic researchers or collaborators under material transfer agreements or confidentiality agreements that provide WARATAH with the right to review potential Publications concerning AZD-103 and Derivatives and to exercise the protections provided for in this Section 5.3 or such other protections agreed to by the Parties. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations presentations, respectively, do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or public presentation be deleted prior to such publication or presentation. In any permitted publication or public presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary scientific standards.

Publications and Presentations. Each Party The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. ImmunoGen agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining the Development and Commercialization of a Licensed Product to the Research Program extent such results refer to, derive from or any Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed Product, otherwise relate to the Licensed Intellectual Property without the prior review by and approval of an authorized representative of the other PartyNovartis. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Accordingly, each Party Novartis shall provide to the other Party ImmunoGen the opportunity to review each of the submitting Party’s Novartis’ proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the publicverbally) that relate to the Research Program contain ImmunoGen’s Confidential Information or disclose any Co-Development Program unpatented Licensed Technology at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party Novartis agrees, upon written request from the other Party ImmunoGen given within such [***] day ]-day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party ImmunoGen is given up to [***] days from the date of such written request to seek appropriate patent protection for any material unpatented Licensed Technology disclosed in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and and, where applicable, approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for or publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or public presentation be deleted prior to such publication or presentation. In any permitted publication or public presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary scientific industry standards.

Publications and Presentations. Each Party The Parties acknowledge that scientific publications and presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. ImmunoGen agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to be published or presented, the results of or information pertaining the Development and Commercialization of a Licensed Product to the Research Program extent such results refer to, derive from or any Development Plan for, or Co-Development of, a Fully-Exercised Co-Developed Product, otherwise relate to the Licensed Intellectual Property without the prior review by and approval of an authorized representative of the other PartyNovartis. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to (a) Development of a Product that is not a Fully-Exercised Co-Developed Product or (b) any Commercialization activities, without the prior review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 of the Securities Act. representative of ELAN. Except with respect to Fully-Exercised Co-Developed Products, ELAN shall be free to publish and present results of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. Accordingly, each Party Novartis shall provide to the other Party ImmunoGen the opportunity to review each of the submitting Party’s Novartis’ proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the publicverbally) that relate to the Research Program contain ImmunoGen’s Confidential Information or disclose any Co-Development Program unpatented Licensed Technology at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party Novartis agrees, upon written request from the other Party ImmunoGen given within such [***] day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party ImmunoGen is given up to [***] days from the date of such written request to seek appropriate patent protection for any material unpatented Licensed Technology disclosed in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and and, where applicable, approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for or publication. Each Party also shall have the right to require that any of its Confidential Information that is disclosed in any such proposed publication or public presentation be deleted prior to such publication or presentation. In any permitted publication or public presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship shall be determined in accordance with customary scientific industry standards.

Publications and Presentations. Each Party agrees that, except as required by Applicable Laws, it shall not publish or present, or permit to The Parties acknowledge that scientific and medical publications and presentations will be published or presented, the results of or information pertaining to the Research Program or any Development Plan for, or Co-Development of, made in a Fully-Exercised Co-Developed Product, without the prior review by and approval of an authorized representative of the other Party. Further, ARCHEMIX shall not publish or present, or allow to be published or presented any information pertaining to manner consistent with (a) Development Third Party agreements in effect as of a Product that is not a Fully-Exercised Co-Developed Product or the Effective Date and (b) subject to subsection (a), GSK Internal Policies, but must be strictly monitored to prevent any adverse effect from premature publication or dissemination of results of the activities hereunder. The Parties will form a publication committee (the “Publication Committee”) as soon as reasonably practicable after the Effective Date, with representation from patent counsel as deemed necessary, which shall work together on publication strategy with the JDC and JCC to coordinate strategy with respect to the U.S. Territory, with coordination by GSK of strategy on a ROW Territory basis, and shall establish rules and procedures for scientific and medical publications and presentations relating to the Development and Commercialization activities, without activities conducted under the prior Collaboration. Such rules and procedures will include requirements for reasonable advance notice and expeditious review by and approval of an authorized Portions of this Exhibit were omitted and have been filed separately with the Secretary of the Commission pursuant to the Company’s application requesting confidential treatment under Rule 406 24b-2 of the Securities ActExchange Act of 1934. representative of ELANproposed publications and presentations, both before and after Commercialization Regulatory Approval is obtained. Except with respect for disclosures permitted pursuant to Fully-Exercised Co-Developed ProductsSection 7.2, ELAN the rules and procedures to be developed by the Publication Committee will require that (i) either Party, its employees or consultants wishing to make a publication shall be free deliver to publish and present results the other Party a copy of Development, including details regarding the relevant Lead Compounds, Clinical Candidates and/or Products, proposed written publication or an outline of an oral disclosure in advance of submission for publication or presentation in accordance with the remainder of this Section 6.3. The Parties acknowledge that scientific publications and public presentations must be strictly monitored to prevent any adverse timelines set forth in GSK Internal Policies or applicable Third Party agreements in effect from premature publication or dissemination of results as of the activities hereunder. AccordinglyEffective Date, each (ii) the reviewing Party shall provide to the other Party the opportunity to review each of the submitting Party’s proposed abstracts, manuscripts or public presentations (including, without limitation, information to be presented verbally to the public) that relate to the Research Program or any Co-Development Program at least [***] days prior to its intended public presentation or submission for publication, and such submitting Party agrees, upon written request from the other Party given within such [***] day period, not to submit such abstract or manuscript for publication or to make such public presentation until the other Party is given up to [***] days from the date of such written request to seek appropriate patent protection for any material in such intended publication or public presentation that it reasonably believes may be patentable. Once such abstracts, manuscripts or presentations have been reviewed and approved by each Party, the same abstracts, manuscripts or presentations do not have to be provided again to the other Party for review for a later submission for publication. Each Party also shall have the right to require that a delay in submission for publication or presentation in accordance with the timelines set forth in GSK Internal Policies or applicable Third Party agreements in effect as of the Effective Date in order to enable patent applications protecting each Party’s rights in such information to be filed, and (iii) each Party shall have the right to prohibit disclosure of any of its Confidential Information that is disclosed in any such proposed publication or public presentation be deleted prior to such publication or presentation. In any permitted publication or public presentation by a Party, the other Party’s contribution shall be duly recognized, and co-authorship ownership shall be determined in accordance with customary scientific standardsGSK Internal Policies. In negotiating agreements with Third Parties, each Party shall use Commercially Reasonable Efforts to obtain the agreement of such Third Party to the timelines for review and delay of submission as set forth in GSK Internal Policies.